BioSpace News Archive

SOPHiA GENETICS SA (Nasdaq: SOPH) today announced it will report financial results for the second quarter of 2021 before market open on Thursday, September 9, 2021.

Diadem srl, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease, announced results from a retrospective longitudinal study of its AlzoSure® Predict prognostic biomarker test.

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its half year results ended 30 June 2021 on Thursday, 2 September 2021.

The Delta Dental Institute announced three new research awards to leading health research institutions.

Afimmune, a clinical stage drug discovery company focused on the development of biologically active lipids for the treatment of inflammatory and cardiometabolic diseases, announced key findings with Epeleuton in a well-established hamster model for SARS-CoV-2 infection.

Vicore Pharma Holding AB publishes the interim report for the second quarter 2021.

Royal Philips announced the launch of its digital experience during the virtual European Society of Cardiology 2021 Congress, taking place August 27-30, during which it will showcase its latest suite of solutions to help improve outcomes for patients with cardiovascular disease by enabling quick, confident diagnoses, and efficient, effective treatments.

Nevro Corp. announced that D. Keith Grossman, Nevro’s Chairman, CEO and President, will present at the Baird 2021 Global Healthcare Conference on Wednesday, September 15, 2021 at 10:50 am Eastern Time / 7:50 am Pacific Time.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced preliminary results of a new preclinical study showing strong inhibition by opaganib [1] of Delta variant replication while maintaining cell viability at relevant concentrations.

Protalix BioTherapeutics, Inc. today announced that it has completed exchanges (the “Exchanges”) of the Company’s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the “2021 Notes”) with institutional note holders of a substantial majority of the 2021 Notes.